Life sciences and biopharma companies often rely on clinical trial results and "clinically proven effective" language in patent claims, but this approach carries significant risks if key details are publicly disclosed before...more
10/2/2025
/ Bayer ,
CAFC ,
Clinical Trials ,
Life Sciences ,
Mylan Pharmaceuticals ,
Obviousness ,
Patent Applications ,
Patent Invalidity ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prior Art
The U.S. Patent and Trademark Office ("USPTO") raised patent fees and introduced new surcharges....more